Customer Center

Samyang News

Samyang News
Samyang Biopharmaceuticals Corp. Wins ‘Palseron Inj.’ Patent Suit Print
Affiliates Samyang Biopharm Writer administrator Hits 2339 Date 2018.01.03

 

Samyang Biopharmaceuticals Corporation has won a first a patent suit on Palseron (Ingredient: Palonosetron Hydrochloride) against a Switzerland-based pharmaceutical company, Helsinn Healthcare SA.

 

On December 21, 2017, the 63rd Civil Affairs Division of the Seoul Central District Court ruled that all of the plaintiff’s claims in relation to patent infringement prohibition and prevention for ‘Alroxi’ (Ingredient: Palonosetron Hydrochloride) filed by Helsinn Healthcare and CJ Healthcare in November 2016, would be dismissed.

 

Alroxi, developed by Helsinn Healthcare, is a drug that inhibits nausea and vomiting that occurs in patients undergoing chemotherapy. CJ Healthcare signed an exclusive distribution agreement with Helsinn Healthcare and has been selling Alroxi in Korea since 2007. Its domestic market size is valued at about KRW 25 billion.

 

Samyang Biopharmaceuticals Corp. avoided patent infringement by developing a technology that secures the stability of the drug without using antioxidants (EDTA), a composition of Alroxi. In May of last year Samyang Biopharmaceuticals Corp. utilized this technology to launch ‘Palseron Inj.’ in Korea. When a generic drug product is released, the prices of both the originator and generic medication fall, reducing the financial burden on patients and cutting the overall health insurance budget.

 

A Samyang Biopharmaceuticals Corp. representative explained, “Breaking away from the fixed idea that antioxidants must be used to ensure stability, we identified the root cause that compromises the drug’s stability and developed a product that secures stability without antioxidants (EDTA), which is included in the existing patent.”

 

Meanwhile, an associate at Boryung Pharmaceutical responsible for sales of Palseron Inj. added, “Samyang Biopharmaceuticals Corp.’s excellent quality and Boryung Pharmaceutical’s, business channels and marketing experience in the oncology market will produce a great synergy.”

이전 다음글 제목을 나타낸 표
Prev Samyang Biopharmaceuticals Corp. Signs Technology Transfer Agreement with KIST for Anticancer Immunotherapy Drug 2018.01.16
Next 300 Million Won Donation for Helping Neighbors in Need 2017.12.28